Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah I agree. J&J has been doing the job up until omicron. As for side effects after vaccine seems to depend on the individual. To be fair I was in some crowded areas the last week so probably my own dumb fault. Stay healthy.
Certainly seems that way. Well, let’s hope we all get better fast and stick out this ride. We’ve waited this long…
Sorry to hear. I think I have it. I feel pretty much like I did after receiving vaccine…aches, pains, headache, fatigued. I recently got the J&J booster. Seems like omicron just laughs at that. Hopefully, will feel better tomorrow.
I do agree with timeframe of April/May but sure would be nice to get an indicator earlier. Also, I like Ecomike thinking they may have found other uses/advantages.
Am I the only one thinking that $1 by year end would be awesome? I like the optimism from others but just don’t see it. Hope I’m wrong!!!
Doc replied to the tweet on marketing in his typical optimistic and vague way. However, the original post he replied to was valid. It will be interesting to see how this shakes out. How can they effectively differentiate, educate, and persuade purchases on something that seems too good to be true. Marketing isn’t my area of expertise but hopefully their partner can make this happen.
Not sure how to phrase this, but does the virus attack the body’s vitamin D3 reserve/amount? The reason I ask is that I know several people including myself that were tested for vitamin D levels and the results were all well below the minimum acceptable level.
I’m not counting on much of a bump when the results come out UNLESS big pharma buys us out. It’s been quite a lesson and eye opener to the process for me. Tough for the little guy to make it on their own. Merck approval was unbelievable while RVVTF just wallowing with a 20 year track record of safety.
Maybe MF surprises us all but seems like the Q4 results milestone was missed and with every day delayed the value seems to diminish on buc.
Maybe I’m wrong but I would think MF would know if results (good or bad) will be available before EOY. If they aren’t, then I d like some communication to shareholders that the Q4 timeline was not met.
Yep. Based on the interim results for Pfizer it makes you think buc results are marginal. Even if they are great, I doubt better than what was stated in the Pfizer PR. So, if parity or below the SP won’t move in the giant steps once hoped for.
Even from a revenue standpoint I wonder about the impact. Perhaps someone with more knowledge can I answer, but with Merck and Pfizer sales, do you really see doctors prescribing buc over them?
Just my opinion, but we have a long way to go. The Samsung news is very encouraging but the timeline is not an overnight exercise. Until there are some results to report I don’t see too much moving this stock upwards. So, it will move sideways or slightly down as people get impatient and sell.
I still believe in this stock but have re-calibrated on when it will take off. Kinda like the good doctor said, don’t get caught up in the day to day SP and trust in the plan.
Thanks for taking the time to provide such a thorough response. I was also a HMBL investor when it was TSNP. I got out post split as it continued to drop. Ken doesn’t seem worried about a RS if it’s for the right reason. He is actually one of the reasons I hold for the long term. This ain’t his first rodeo.
One question I had was his answer about HMBL Interestingly they had PR drop today. I’d like to hear a deeper answer regarding the differences in blockchain strategies. Or perhaps someone smart on this board can shed some light.
https://finance.yahoo.com/news/humbl-blocks-announce-strategic-collaboration-194300436.html
Ditto. Glad everything went well. Hope recovery goes smoothly too!
I agree on trying to settle it sooner than later. Just noise that doesn’t help and brings about more uncertainty which is not good when you are an OTC
I completely agree. I’ve said before that these guys are scientists. They need someone that can increase shareholder value. I’m talking about muzzling their tweets. Get a proper PR and investor relations person. If you want to be traded li’e a big board company start acting like it.
Agree. It’s funny…at first I’m thinking that was too harsh but it’s dead on point. It’s astonishing no media outlets yet.
I have not seen any impact on SP when making it to OTCQB. I like that it shows the maturation of the company but we need revenue to move the price. Something to show that the plan is being realized.
What worries me is that I don’t see anyway to uplist without a RS. My history with RS hasn’t been good. It seems like it’s going to Blake a lot of patience to see this through as a true investment versus a short term play. Ken has alluded to a lot of announcements coming so perhaps he will share more of his plan to increase shareholder value.
Just my opinion…of the few OTC I own WDLF is by far the most professional. As Ken said in the podcast, “we’re not a normal OTC”. Granted, that’s no guarantee of success but it gives some comfort that they know what they are doing.
Long term there’s going to have to be a RS to get on the Nasdaq. I just don’t see how we can climb to the needed stock price for qualification. But agree, no RS in near term
Yeah so true. Hats off to filling the funnel but we need to show that we can get stuff to market. I know it’s early on many of these but we need to get bucillamine under belt, learn from it, and improve.
Great catch on AP. I don’t recall then picking up anything for RVVTF
So this was actually St Judes and UCC research, correct?
Not sure I see why it will be fast tracked. Regeneron is way ahead and has mAB. Granted, different technology but does ENZC have enough to be a differentiator that would result in fast tracking? Although I’m along on ENZC I don’t see it.
Anyone else have any reasons to support otherwise?
Correct! Unfortunately that’s part of the problem.
Problem is Florida is publicly touting Regeneron.
He mentioned multiple times that patient recruitment has not been an issue. I wonder if that was directed at some critical shareholders. I admit I have been critical of that aspect. MF admits to following the social media boards and commentary so I’m sure he’s read it.
Personally, I have been waiting for communication like this. Confirmation that recruitment has not been a problem. From the cheap seats I think it’s easy to speculate the delays might be around recruitment. In the end, I have no problem with MF getting the last laugh.
It does seem that the bucillamine study is being done in a way that if the results are good it will be hard to poke holes in the study. That’s my non professional opinion:)
I couldn’t agree more. Look at the coverage Pfizer is already getting. Even good results won’t move the needle as much as I had once thought. Owning this stock has been a learning experience.
Great point. It’s going to be fascinating to see how it shakes out. In near term I want to see how Lonza handles the PR this week. I still think that ENZC was premature with the announcement. I’ve not seen this before…where one company announces and the other announces at a later date.
Unfortunately the market thinks they’re worth 0.5 billion
I really think this news is non news. We need results and until then everything is just noise.
Were they talking about Sotrovimab as the monoclonal antibody that didn’t work?
I went on yahoo and went to see if there was any discussion on Lonza board. Nothing. Very quiet board. If I was a Lonza SH I’d be excited too.
With the SP so low I’m surprised Jeff doesn’t execute some type of token buyback to make it look like he’s trying to fulfill the promise.
I did not see the news for NASDAQ up list…only OTCQB. Did I miss?
What is the timetable on the hard data?
To me it would be nice if Intel took them under their wing a bit more. These guys are scientists. They need help finding top notch PR, controlling messaging, etc.
I hope you are right. Personally I haven’t seen many jumps with the OTCQB up list. If they can post big revenues I think that will be a bigger catalyst.
I’ve actually been surprised there hasn’t been more of a run up knowing theres an announced PR planned.